tiprankstipranks
Trending News
More News >
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
US Market

KalVista Pharmaceuticals (KALV) Stock Forecast & Price Target

Compare
579 Followers
See the Price Targets and Ratings of:

KALV Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
KalVista
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KALV Stock 12 Month Forecast

Average Price Target

$32.13
▲(102.84% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for KalVista Pharmaceuticals in the last 3 months. The average price target is $32.13 with a high forecast of $39.00 and a low forecast of $27.00. The average price target represents a 102.84% change from the last price of $15.84.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","40":"$40","15.25":"$15.25","23.5":"$23.5","31.75":"$31.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$39.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,15.25,23.5,31.75,40],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.92,15.849230769230768,17.77846153846154,19.707692307692305,21.636923076923075,23.566153846153846,25.495384615384616,27.424615384615386,29.353846153846153,31.28307692307692,33.21230769230769,35.14153846153846,37.07076923076923,{"y":39,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.92,15.32076923076923,16.72153846153846,18.122307692307693,19.52307692307692,20.923846153846153,22.324615384615385,23.725384615384613,25.126153846153848,26.526923076923076,27.927692307692308,29.32846153846154,30.729230769230767,{"y":32.13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.92,14.926153846153847,15.932307692307692,16.93846153846154,17.944615384615386,18.950769230769232,19.956923076923076,20.963076923076922,21.96923076923077,22.975384615384616,23.981538461538463,24.987692307692306,25.993846153846157,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.61,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.27,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.47,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.91,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.16,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.92,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.21,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.29,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.05,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.92,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$39.00Average Price Target$32.13Lowest Price Target$27.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies
$38
Buy
139.90%
Upside
Reiterated
12/22/25
Jefferies Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV)
Bank of America Securities Analyst forecast on KALV
Bank of America Securities
Bank of America Securities
$30
Buy
89.39%
Upside
Reiterated
12/18/25
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (NASDAQ: KALV) and Novan (NASDAQ: NOVN)
JonesTrading
$37
Buy
133.59%
Upside
Reiterated
12/03/25
Positive Outlook for KalVista Pharmaceuticals Amid Competitive Developments and Market Growth Potential
Needham
$28
Buy
76.77%
Upside
Reiterated
12/03/25
KalVista Pharmaceuticals: Strong Market Position and Promising Future with Ekterly Leading the Way
Stifel Nicolaus Analyst forecast on KALV
Stifel Nicolaus
Stifel Nicolaus
$20$39
Buy
146.21%
Upside
Assigned
12/03/25
KalVista Pharmaceuticals: Strategic Market Position and Strong Buy Recommendation
H.C. Wainwright Analyst forecast on KALV
H.C. Wainwright
H.C. Wainwright
$20$27
Buy
70.45%
Upside
Reiterated
11/13/25
Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (NASDAQ: OBIO), Corbus Pharmaceuticals (NASDAQ: CRBP) and KalVista Pharmaceuticals (NASDAQ: KALV)
TD Cowen Analyst forecast on KALV
TD Cowen
TD Cowen
$30
Buy
89.39%
Upside
Reiterated
11/13/25
Positive Outlook for KalVista Pharmaceuticals: Buy Rating Affirmed Due to Strong Financial Performance and Market Demand for Ekterly
Citizens JMP Analyst forecast on KALV
Citizens JMP
Citizens JMP
$29$28
Buy
76.77%
Upside
Reiterated
11/11/25
KalVista price target lowered to $28 from $29 at Citizens JMPKalVista price target lowered to $28 from $29 at Citizens JMP
Leerink Partners Analyst forecast on KALV
Leerink Partners
Leerink Partners
Buy
Reiterated
10/15/25
Cantor Fitzgerald Analyst forecast on KALV
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
03/26/25
Cantor Fitzgerald reiterates Overweight Rating on Kalvista Pharmaceuticals Inc (KALV)Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Kalvista Pharmaceuticals Inc (NASDAQ: KALV).
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies
$38
Buy
139.90%
Upside
Reiterated
12/22/25
Jefferies Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV)
Bank of America Securities Analyst forecast on KALV
Bank of America Securities
Bank of America Securities
$30
Buy
89.39%
Upside
Reiterated
12/18/25
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (NASDAQ: KALV) and Novan (NASDAQ: NOVN)
JonesTrading
$37
Buy
133.59%
Upside
Reiterated
12/03/25
Positive Outlook for KalVista Pharmaceuticals Amid Competitive Developments and Market Growth Potential
Needham
$28
Buy
76.77%
Upside
Reiterated
12/03/25
KalVista Pharmaceuticals: Strong Market Position and Promising Future with Ekterly Leading the Way
Stifel Nicolaus Analyst forecast on KALV
Stifel Nicolaus
Stifel Nicolaus
$20$39
Buy
146.21%
Upside
Assigned
12/03/25
KalVista Pharmaceuticals: Strategic Market Position and Strong Buy Recommendation
H.C. Wainwright Analyst forecast on KALV
H.C. Wainwright
H.C. Wainwright
$20$27
Buy
70.45%
Upside
Reiterated
11/13/25
Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (NASDAQ: OBIO), Corbus Pharmaceuticals (NASDAQ: CRBP) and KalVista Pharmaceuticals (NASDAQ: KALV)
TD Cowen Analyst forecast on KALV
TD Cowen
TD Cowen
$30
Buy
89.39%
Upside
Reiterated
11/13/25
Positive Outlook for KalVista Pharmaceuticals: Buy Rating Affirmed Due to Strong Financial Performance and Market Demand for Ekterly
Citizens JMP Analyst forecast on KALV
Citizens JMP
Citizens JMP
$29$28
Buy
76.77%
Upside
Reiterated
11/11/25
KalVista price target lowered to $28 from $29 at Citizens JMPKalVista price target lowered to $28 from $29 at Citizens JMP
Leerink Partners Analyst forecast on KALV
Leerink Partners
Leerink Partners
Buy
Reiterated
10/15/25
Cantor Fitzgerald Analyst forecast on KALV
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
03/26/25
Cantor Fitzgerald reiterates Overweight Rating on Kalvista Pharmaceuticals Inc (KALV)Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Kalvista Pharmaceuticals Inc (NASDAQ: KALV).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering KalVista Pharmaceuticals

1 Month
xxx
Success Rate
11/23 ratings generated profit
48%
Average Return
+2.25%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 47.83% of your transactions generating a profit, with an average return of +2.25% per trade.
3 Months
xxx
Success Rate
14/23 ratings generated profit
61%
Average Return
+12.70%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.87% of your transactions generating a profit, with an average return of +12.70% per trade.
1 Year
Joseph SchwartzLeerink Partners
Success Rate
19/23 ratings generated profit
83%
Average Return
+24.97%
reiterated a buy rating 2 months ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 82.61% of your transactions generating a profit, with an average return of +24.97% per trade.
2 Years
xxx
Success Rate
14/14 ratings generated profit
100%
Average Return
+29.24%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +29.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KALV Analyst Recommendation Trends

Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
21
20
10
16
15
Buy
6
2
2
2
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
22
12
18
16
In the current month, KALV has received 16 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. KALV average Analyst price target in the past 3 months is 32.13.
Each month's total comprises the sum of three months' worth of ratings.

KALV Financial Forecast

KALV Earnings Forecast

Next quarter’s earnings estimate for KALV is -$0.84 with a range of -$1.08 to -$0.64. The previous quarter’s EPS was ―. KALV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year KALV has Performed in-line its overall industry.
Next quarter’s earnings estimate for KALV is -$0.84 with a range of -$1.08 to -$0.64. The previous quarter’s EPS was ―. KALV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year KALV has Performed in-line its overall industry.

KALV Sales Forecast

Next quarter’s sales forecast for KALV is $20.37M with a range of $13.00M to $25.90M. The previous quarter’s sales results were ―. KALV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year KALV has Performed in-line its overall industry.
Next quarter’s sales forecast for KALV is $20.37M with a range of $13.00M to $25.90M. The previous quarter’s sales results were ―. KALV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year KALV has Performed in-line its overall industry.

KALV Stock Forecast FAQ

What is KALV’s average 12-month price target, according to analysts?
Based on analyst ratings, KalVista Pharmaceuticals’s 12-month average price target is 32.13.
    What is KALV’s upside potential, based on the analysts’ average price target?
    KalVista Pharmaceuticals has 102.84% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is KALV a Buy, Sell or Hold?
          KalVista Pharmaceuticals has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is KalVista Pharmaceuticals’s price target?
            The average price target for KalVista Pharmaceuticals is 32.13. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $39.00 ,the lowest forecast is $27.00. The average price target represents 102.84% Increase from the current price of $15.84.
              What do analysts say about KalVista Pharmaceuticals?
              KalVista Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of KALV?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.